FDA Releases Draft Guidance on Electronic Submission of Expedited Safety Reports for IND-Exempt Bioavailability/Bioequivalence Studies

Summary

The FDA has made available a draft guidance for industry outlining procedures for submitting expedited safety reports from IND-exempt bioavailability/bioequivalence studies electronically through the FDA Adverse Event Reporting System (FAERS) database.